%0 Journal Article
%A Biederstädt, Alexander
%A Bassermann, Florian
%A Hecker, Judith S
%T Allogeneic CAR-engineered cellular therapy for relapsed and refractory large B cell lymphoma: a systematic review and meta-analysis.
%J Frontiers in immunology
%V 16
%@ 1664-3224
%C Lausanne
%I Frontiers Media
%M DKFZ-2025-01510
%P 1585556
%D 2025
%X Relapsed/refractory (r/r) large B-cell lymphoma (LBCL) remains a difficult-to-treat disease with limited treatment options and high unmet clinical need, necessitating the development of new therapies with greater potency and broader applicability. While autologous chimeric antigen receptor (CAR)-T cell therapies have transformed the treatment landscape, 60-65
%K Humans
%K Immunotherapy, Adoptive: methods
%K Immunotherapy, Adoptive: adverse effects
%K Receptors, Chimeric Antigen: immunology
%K Receptors, Chimeric Antigen: genetics
%K Lymphoma, Large B-Cell, Diffuse: therapy
%K Lymphoma, Large B-Cell, Diffuse: immunology
%K Treatment Outcome
%K Neoplasm Recurrence, Local: therapy
%K Killer Cells, Natural: immunology
%K Killer Cells, Natural: transplantation
%K Transplantation, Homologous
%K CRISPR gene editing (Other)
%K adoptive cell therapy (ACT) (Other)
%K allogeneic CAR-NK cells (Other)
%K allogeneic CAR-T cells (Other)
%K cellular engineering (Other)
%K clinical trial (Other)
%K large B cell lymphoma (Other)
%K precision gene editing (Other)
%K Receptors, Chimeric Antigen (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:40698082
%2 pmc:PMC12279871
%R 10.3389/fimmu.2025.1585556
%U https://inrepo02.dkfz.de/record/303085